<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643249</url>
  </required_header>
  <id_info>
    <org_study_id>KL1333 2020-103</org_study_id>
    <nct_id>NCT04643249</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of KL1333 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abliva AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abliva AB</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate&#xD;
      the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and&#xD;
      CYP3A4 in Healthy Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase I, open-label, fixed-sequence, crossover study to investigate the effect&#xD;
      of coadministration of KL1333 on the PK of repaglinide, caffeine, omeprazole, midazolam,&#xD;
      bupropion, dextromethorphan, and flurbiprofen in healthy male and female subjects. Potential&#xD;
      subjects will be screened to assess their eligibility to enter the study within 28 days prior&#xD;
      to the first dose administration. Subjects will be admitted into the clinical research unit&#xD;
      (CRU) on Day -1 and be confined to the CRU until discharge on Day 19. Subjects will return to&#xD;
      the CRU for a follow-up visit 5 to 7 days after the last dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Actual">December 17, 2020</completion_date>
  <primary_completion_date type="Actual">December 17, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All subjects are treated in the same arm, but in a crossover manner.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the effect of KL1333 on the PK of repaglinide, caffeine, omeprazole, midazolam, bupropion, dextromethorphan, and flurbiprofen in healthy subjects.</measure>
    <time_frame>day 14</time_frame>
    <description>Area under the curve AUC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of the single-dose PK of repaglinide, caffeine, omeprazole, midazolam, bupropion, dextromethorphan, and flurbiprofen administered alone and in the presence of KL1333 in healthy subjects</measure>
    <time_frame>Day 14</time_frame>
    <description>Area under the curve AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of the safety and tolerability of KL1333 when coadministered with repaglinide, caffeine, omeprazole, midazolam, bupropion, dextromethorphan, and flurbiprofen in healthy subjects.</measure>
    <time_frame>Day 14</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Mitochondrial Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL1333</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>Syrap</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam injection</intervention_name>
    <description>solution for injection</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Midazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Tablet or capsule</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, of any race, between 18 and 65 years of age, inclusive.&#xD;
&#xD;
          2. Weight â‰¥50 kg and body mass index between 18.0 and 32.0 kg/m2, inclusive.&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory&#xD;
             evaluations (congenital nonhaemolytic hyperbilirubinaemia [eg, suspicion of Gilbert's&#xD;
             syndrome based on total and direct bilirubin] is not acceptable) at screening and&#xD;
             check-in as assessed by the investigator.&#xD;
&#xD;
          4. Females will not be pregnant or lactating, and females of childbearing potential and&#xD;
             males will agree to use contraception as detailed in Appendix 4.&#xD;
&#xD;
          5. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
          6. Able to perform all protocol-specified assessments and comply with the study visit&#xD;
             schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, haematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the investigator.&#xD;
&#xD;
          2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, including KL1333 or its excipients, unless approved by the&#xD;
             investigator.&#xD;
&#xD;
          3. History of gastroesophageal reflux disease, gastric erosions, peptic ulcer disease, or&#xD;
             gastrointestinal bleeding episodes.&#xD;
&#xD;
          4. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs including cholecystectomy&#xD;
             (uncomplicated appendectomy and hernia repair will be allowed).&#xD;
&#xD;
          5. History of malignancy of any organ system other than localised basal cell carcinoma of&#xD;
             the skin, treated or untreated, within 5 years prior to screening, regardless of&#xD;
             whether there is evidence of local recurrence or metastases.&#xD;
&#xD;
          6. History of clinically significant illness or surgery within 4 weeks prior to&#xD;
             screening, as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Volunteer recruitment center Covance Leeds Covance Leeds</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

